相关实验视频

Updated: Jun 14, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

向非编码RNA作为腹膜转移中的有希望的生物标志物:背景,机制和治疗方法

Yiping Zhang¹, Jun Xie¹

¹School of Life Sciences, Fudan University, Shanghai 200438, China; Wanchuanhui (Shanghai) Medical Technology Co., Ltd, Shanghai 201501, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|September 3, 2024

概括

非编码RNAs (ncRNAs) 是理解胃肠癌中腹转移的关键. 研究强调了它们在诊断,预后和PM的新疗法中的作用,改善了患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

来自胃肠道 (GI) 癌症的腹膜转移 (PM) 呈现出复杂的病理生理学和有限的治疗选择,显著恶化了患者的预后.
非编码RNAs (ncRNAs),包括microRNAs (miRNAs) 和长非编码RNAs (lncRNAs),越来越多地被认为它们在癌症发育,进展和治疗耐药性方面的关键作用.

研究的目的:

总结最近关于ncRNAs在肠胃癌中腹膜转移 (PM) 的作用的发现.
突出ncRNAs作为生物标志物的潜力,用于早期检测,预后和PM的治疗点.
讨论涉及ncRNAs和PM多式治疗的新兴治疗策略.

主要方法:

关于与腹膜转移有关的ncRNA研究近期进展的文献综述.
在肠道癌转移中的ncRNA调节背后的分子机制的分析.
综合了目前关于ncRNA个人资料在PM中的诊断和预后影响的数据.

主要成果:

ncRNAs显著影响PM中的瘤发生,进展,转移和治疗耐药性.
ncRNA概况与PM患者的生存率,治疗反应和复发风险存在相关性.
针对ncRNAs的创新疗法和像HIPEC手术这样的多式疗法显示出有前途的结果.

结论:

ncRNAs具有改进诊断,预后和改善肠胃癌中腹转移的治疗的变革潜力.
通过ncRNA研究对PM的分子表征对于开发个性化和有效的临床策略至关重要.
进一步研究ncRNA功能和治疗应用对于推进PM管理至关重要.

关键词:

在 LncRNAs 中.转移转移转移转移这就是米RNAs.没有编码的RNAs.腹膜转移的发生.

更多相关视频

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...